Genteric

Genteric was a biotechnology company that pioneered a novel approach to gene therapy by using the salivary gland as a site for protein production and systemic delivery. The company's platform aimed to treat chronic diseases by delivering therapeutic genes directly to salivary glands, which would then secrete the resulting proteins into the bloodstream. This method was intended to provide a less invasive and more controlled alternative to traditional protein injections or systemic gene therapy. Genteric's lead programs focused on the delivery of insulin for diabetes and growth hormone for endocrine disorders. Although the company attracted significant venture capital from top-tier firms, it ultimately ceased operations in the mid-2000s without advancing products to the market.